Objectives To evaluate whether the requirement of “minimal risk and burden” for paediatric research without direct benefit to the subjects compromises the ability to obtain data necessary for improving paediatric care. To provide evidence-based reflections on the EU recommendation that allows for a higher level of risk.
Design and setting Systematic analysis of the approval/rejection decisions made by the Dutch Central Committee on Research involving Human Subjects (CCMO).
Review methods The analysis included 165 proposals for paediatric research without direct benefit that were reviewed by the CCMO between January, 2000, and July, 2007. A separate, in-depth analysis of all drug studies included 18 early phase drug studies and nine other drug studies without direct benefit.
Results 11 out of 165 studies were definitively rejected because the CCMO did not regard the risk and/or burden to be minimal. In three of these 11 cases (including two early phase drug studies) the requirement of minimal risk and burden was cited as the only reason for rejection. Four other early phase drug studies also involved risks and/or burdens that were not regarded to be minimal but were nevertheless approved.
Conclusions The requirement of minimal risk and burden, aiming to protect research subjects, occasionally leads to rejection of protocols. Early phase drug studies relatively often do not comply with the requirement. Committees may find ways to approve important studies that formally should be rejected, but that is not a desirable solution. The regulatory framework should be revised to make such occasional exceptions to the requirement legitimate and transparent.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Drug development for children: how adequate is the current European ethical guidance?
- Ambiguous articles in new EU Regulation may lead to exploitation of vulnerable research subjects
- Improving the Helsinki Declaration's guidance on research in incompetent subjects
- To stop or not to stop: dissent and undue burden as reasons to stop participation in paediatric research
- Process of risk assessment by research ethics committees: foundations, shortcomings and open questions
- Non-therapeutic research with minors: how do chairpersons of German research ethics committees decide?
- Eliminating the daily life risks standard from the definition of minimal risk
- Assessing research risks systematically: the net risks test
- The structure of ethics review: expert ethics committees and the challenge of voluntary research euthanasia
- Pharmacokinetic studies in children: recommendations for practice and research